6LS5 image
Entry Detail
PDB ID:
6LS5
Keywords:
Title:
Structure of human liver FBPase complexed with covalent allosteric inhibitor
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2020-01-17
Release Date:
2020-05-27
Method Details:
Experimental Method:
Resolution:
2.03 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fructose-1,6-bisphosphatase 1
Chain IDs:A, B, C, D
Chain Length:353
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
J.Med.Chem. 63 6238 6247 (2020)
PMID: 32375478 DOI: 10.1021/acs.jmedchem.0c00699

Abstact

Fructose 1,6-bisphosphatase (FBPase) has attracted substantial interest as a target associated with cancer and type 2 diabetes. Herein, we found that disulfiram and its derivatives can potently inhibit FBPase by covalently binding to a new C128 allosteric site distinct from the original C128 site in APO FBPase. Further identification of the allosteric inhibition mechanism reveals that the covalent binding of a fragment of 214 will result in the movement of C128 and the dissociation of helix H4 (123-128), which in turn allows S123 to more easily form new hydrogen bonds with K71 and D74 in helix H3 (69-72), thereby inhibiting FBPase activity. Notably, both disulfiram and 212 might moderately reduce blood glucose output in vivo. Therefore, our current findings not only identify a new covalent allosteric site of FBPase but also establish a structural foundation and provide a promising way for the design of covalent allosteric drugs for glucose reduction.

Legend

Protein

Chemical

Disease

Primary Citation of related structures